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Abstract
SOX8 is an HMG-box transcription factor closely related to SRY and SOX9. Deletion of the gene encoding Sox8 in mice causes
reproductive dysfunction but the role of SOX8 in humans is unknown. Here, we show that SOX8 is expressed in the somatic
cells of the early developing gonad in the human and influences human sex determination. We identified two individuals
with 46, XY disorders/differences in sex development (DSD) and chromosomal rearrangements encompassing the SOX8 locus
and a third individual with 46, XY DSD and a missense mutation in the HMG-box of SOX8. In vitro functional assays indicate
that this mutation alters the biological activity of the protein. As an emerging body of evidence suggests that DSDs and infer-
tility can have common etiologies, we also analysed SOX8 in a cohort of infertile men (n¼274) and two independent cohorts
of women with primary ovarian insufficiency (POI; n¼153 and n¼104). SOX8 mutations were found at increased frequency in
oligozoospermic men (3.5%; P<0.05) and POI (5.06%; P¼4.5105) as compared with fertile/normospermic control popula-
tions (0.74%). The mutant proteins identified altered SOX8 biological activity as compared with the wild-type protein. These
data demonstrate that SOX8 plays an important role in human reproduction and SOX8 mutations contribute to a spectrum of
phenotypes including 46, XY DSD, male infertility and 46, XX POI.
Introduction
Human sex determination is a tightly controlled and highly com-
plex process, where the bipotential gonad anlage develops as one
of two mutually antagonistic fates – the ovary or a testis. SRY is
well established as the primary testis-determining gene on the Y
chromosome. In the XY gonad, SRY acts during embryonal devel-
opment to upregulate the downstream effector SOX9 beyond a
critical threshold, which promotes testis development and in
turn represses ‘ovarian pathways’ in the male gonad through
multiple mechanisms (1,2). In mice, up-regulation of Sox9 in
males is by the synergistic action of Sry with Nr5a1 [also known
as Steroidogenic factor-1 (Sf1)], through binding to multiple ele-
ments within a testis-specific Sox9 enhancer (Tesco) (1). Sox9 ex-
pression is required to establish Sertoli cell identity in the
developing testis (2). Once formed, foetal Sertoli cells produce
anti-Mu¨llerian hormone (AMH) and coordinate the cellular and
morphogenetic events leading to primary sex determination (2).
Although the SOX genes SRY and SOX9 play essential roles in
driving early mammalian testis-determination, emerging evi-
dence suggests the contribution of another Sox gene, Sox8, in mu-
rine testis-determination as well as in the maintenance of
gonadal function. Sox8 shows an overlapping expression pattern
with Sox9 in foetal and adult mouse gonad and functional redun-
dancy between Sox8 and Sox9 occurs during testis development
(3–6). Sox8 XY null mutants show normal testis development but
develop post-natal progressive spermatogenic failure (7).
Development and maintenance of the mammalian gonad is
regulated by a double repressive system, where an equilibrium of
mutually antagonistic pathways must be attained for normal de-
velopment of either the testis or ovaries (2–6). In humans,
changes in this delicate balance can lead to Disorders of (or
Differences in) Sex Development (DSD), which are defined as con-
genital conditions with discordant development of chromosomal,
gonadal or anatomical sex (8). The incidence of DSD has been es-
timated at 1: 2, 500 to 1: 5000 births (9–10). Excluding inborn errors
in steroidogenesis, a molecular diagnosis will be reached in only
20% of all individuals with 46, XY DSD (9). Around 40% of the
cases with 46, XY complete gonadal dysgenesis (CGD) can be ex-
plained by mutations involving three genes SRY, NR5A1 and
MAP3K1 (4,5). Pathogenic variants in other sex-determining genes
such as CBX2, GATA4 or FOG2/ZFPM2 are found in a very small
percentage of cases (9,10). Hence, the aetiology in majority of the
individuals with DSD remain poorly understood.
An emerging body of evidence suggests that DSD and
infertility can have common aetiologies, For example,
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mutations involving NR5A1 (SF-1), a key player in many aspects
of reproductive function including sex determination, are asso-
ciated not only with a spectrum of DSD such as 46, XY CGD, 46,
XY undervirilised males with testes, or 46, XX (ovo)testicular
DSD but also more prevalent forms of human infertility, i.e. 46,
XY men with spermatogenic failure and 46, XX women with pri-
mary ovarian insufficiency (POI) (11–14). Human infertility is a
major human health issue; one in seven couples worldwide
have problems conceiving and both men and women are af-
fected equally (15,16). POI is characterised by primary or second-
ary amenorrhea, high gonadotropin levels (FSH above 40iU/l on
two occasions at least a month apart) and estrogen deficiency in
women under the age of 40 years (17). Male infertility includes
azoospermia characterized by complete absence of spermato-
zoa in the ejaculate, whereas oligozoospermia is defined as
sperm concentrations below the World Health Organization ref-
erence level of 15 106 sperm/ml (18). The underlying basis for
either male or female infertility is complex, including both
physiological and environmental factors as well as gene muta-
tions. Although mouse models have revealed hundreds of genes
that are associated with fertility, only a few single-gene defects
that cause male and/or female infertility have been identified in
humans (12,13,19–24). Here, for the first time we demonstrate
that mutations involving the human SOX8 gene are associated
with a range of phenotypes including 46, XY DSD as well as
male infertility and ovarian insufficiency in females.
Results
Rearrangements involving the SOX8 locus and 46,
XY DSD
Patient 1 is a phenotypic female who presented at the age
of 27 years with primary amenorrhea (Patient 1, Table 1).
Chromosome analysis showed a 46, XY karyotype with a para-
centric inversion [46, XY, inv(16)(p13.3p13.1); Fig. 1A and B],
which was confirmed by FISH analysis (Fig. 1C). Her parents and
unaffected sister were not available for analysis. Hence, it is un-
known if this rearrangement is de novo, however, this rearrange-
ment has not been reported in control databases. Array-CGH
did not reveal any chromosomal imbalances, including the
chr16 short arm, associated with the phenotype. The centro-
meric breakpoint was mapped within the BAC clone RP11–
609N14 (chr16: 10428838–10600163) (Fig. 1D). The telomeric
breakpoint was mapped within the BAC clone RP11–728H8 be-
tween chr16; 814 190–962 809 (Fig. 1E). Whole genome sequenc-
ing confirmed these results and indicated a centromeric
breakpoint at chr16: 10 522 104–10 522 114 and a telomeric
breakpoint at chr16: 881 929–881 965. The transcription initia-
tion site of the SOX8 gene is at chr16: 1 031 808. Therefore, the
breakpoint is located 150 Kb upstream of SOX8 (Fig. 1A). A bi-
lateral gonadectomy revealed two small gonads, which on his-
tological examination showed two streak-like gonads with no
germ cells or differentiated tissue (Fig. 2A).
Table 1. Phenotypes, genetics and clinical investigations of 46, XY DSD with mutations involving the SOX8 locus (patients 1 and 2) or gene (patient 3)
Patient Phenotype Clinical presentation
(age)
Genetics Hormonal pro-
file(normal range)
Genitalia and gonads Diagnosis
1 Female Primary amenorrhea
with female external
genitalia
46, XY, inv(16)
(p13.3p13.1)
FSH: 59.5 iU/l
(2.0–15.0)
Bilateral streak gonads
with fallopian tubes.
Stromal-like tissue
with no evidence for
testicular tissue or
follicles.
46, XY CGD
LH: 23.6 iU/l
(2.1–14.9)
Small immature ute-
rus, 43 2230 mm
(27 years).T: 0.7 ng/ml
(2.70–9.00)
2 Female at birth then
changed to male
assignment
Ambiguous genitalia
(birth), mild anaemia,
skeletal anomalies,
mild developmental
delay
46, XY FSH: 2.31 iU/l
(0.16–4.1 mIU/ml)
At birth clitorophallic
structure (1 1cm)
with urethral mea-
tus at base. Fused
labioscrotal folds
with palpable go-
nads (R:
1.2 0.6 0.8cm, L:
1.1 0.4 0.7cm).
No uterus or vagina.
Testis histology
showed seminifer-
ous tubules, vari-
able germ cells and
reduced Leydig cell
numbers.
46, XY severe
undervirilization
arr[h19] 16p13.3
(137, 893–992,
302)3
LH: 17.35 iU/l
(0.02–7.0 mIU/ml)
T: 1.38 ng/ml (0.6–4
ng/ml)
DHT 36 ng/dL (12–85)
3 Female Primary amenorrhea
(16 years)
46, XY SOX8 Elevated FSH, LH:
undetectable T
levels
Bilateral streak gonads
with absent uterus.
Epididymis-like
structure present.
46, XY PGD
p.Glu156Asp
PolyPhen2 Score
0.999
CGD: complete gonadal dysgenesis; PGD: partial gonadal dysgenesis; FSH: Follicle stimulating hormone; LH: Luteinizing hormone. All mutations are heterozygous.
1230 | Human Molecular Genetics, 2018, Vol. 27, No. 7
Patient 2 is a 46, XY girl with mild post-natal anaemia, sleep-
iness, poor feeding and tachycardia (Patient 2, Table 1 and
Supplementary Material). Physical examination showed a
prominent forehead and ophthalmological evaluation revealed
small bilateral chorioretinal colobomas. At birth the genitalia
consisted of a midline clitorophallic structure with bilateral
labioscrotal folds, which were fused at the midline. On pelvic ul-
trasound, there was no uterus or vagina noted and gonads and
epididymides were identified in the labia bilaterally. Pituitary
hormone levels were within normal limits. The child was as-
signed male and at 10 months of age underwent the first stage
of surgery for hypospadias, chordee repair and posterior ure-
thral mobilization, and scrotoplasty. At 2 years 10 months the
patient underwent bilateral orchidopexy, bilateral inguinal her-
nia repair, and bilateral gonadal biopsy. Gonadal histology
showed seminiferous cords, variable germ cells and reduced
Leydig cell numbers by calretinin staining (Fig. 2B–E). aCGH de-
tected a two copy DNA gain in the 16p13.3 region [arr(h19)
16p13.3(137 893–992 302]4, log2¼þ1), spanning at least 854 kb
(Fig. 1F), resulting in tetrasomy of that DNA segment. This re-
gion comprises at least 27 genes, including the a-globin gene
cluster (Supplementary Material, Table S1). FISH analyses using
RP11–598I20 BAC probe on cultured peripheral blood samples
from the patient and both parents indicated that the tetrasomy
was a de novo event (Fig. 1G and H). The centromeric breakpoint
of this triplication was located within the intron 2 of the LMF1
(lipase maturation factor 1) gene, 39.5 kb upstream of the
SOX8 gene. Homozygous, loss-of-function LMF1 gene mutations
are responsible for hypertriglyceridemia and decreased lipase
activity and hence this gene was not considered to be associ-
ated with the phenotype (25). Interestingly, SOX8-specific en-
hancer elements are included in the triplication (26). Together,
these data suggest that rearrangements at the SOX8 resulting in
dysregulation of SOX8 expression could negatively impact
testis-determination and may result in 46, XY DSD including
disorders of testis-determination. Consistent with this postula-
tion, we observed that SOX8 is co-expressed with NR5A1 and
SOX9 in the early stages of human testis-determination in
Sertoli cells and Leydig cells as well as in Sertoli and Leydig cells
in adult men (Fig. 3A, Supplementary Material, Fig. S1). Single
cell RNA sequencing on XY mouse gonads during sex determi-
nation has also demonstrated that Sox8 is co-expressed with
other genes involved in sex determination including Nr5a1,
Dmrt1 and Gata4 (27).
Figure 1. Chromosomal rearrangements at the SOX8 locus associated with 46, XY DSD. (A) Schematic representation of the 16p inversion in patient 1 indicating the
genes and clones of the region and the position of the telomeric breakpoint (TB) and centromeric breakpoints (CB). The position of the transcription initiation site of
the SOX8 gene is indicated (chr16: 1 031 808), the Sox8 enhancer elements (E1–E4) and the position of the BACs used for FISH analysis. Patient 1 with (B) GTG banding
showing the rearranged chromosome 16 (arrow). (C) FISH on metaphases with BAC RP11–161M6 (green; chr16: 991, 108–1, 141, 991- UCSC Genome Browser; GRCh37/
hg19) and RP11–297M9 (red; chr16: 9, 727, 655–9, 920, 250) confirming the paracentric inversion (arrow). (D) The CB is located within the clone, RP11–609N14 on
16p13.13). (E) The TB mapped within RP11–728H8, on 16p13.3 (arrows). Patient 2 (F) Chromosome 16p rearrangement. The aCGH profile indicated an 854 kb triplication
in the 16p13.3 region. Affected region is indicated by a blue bar. Red rectangles outline the triplication breakpoints. A magnified view of the triplication breakpoints
shows, on the left, a CB located in the intron 1 of the NPRL3 gene. The 16p13.3 triplication starts at chr16: 137893 position and spans proximally including the a-globin
genes (HBZ, HBM, HBA1, HBA2, and HBQ1) and their upstream cis-regulatory elements R1-R4 (red bars). On the right, the TB of the triplication (chr16: 992, 302) is located
39.5 kb upstream of the SOX8 gene. The SOX8-specific enhancers are mapped within the triplicated segment. Genes are indicated by black arrows with vertical lines
specifying exons. Arrows correspond to a direction of gene transcription. (G) Interphase FISH analysis using RP11–598 I20 (16p13.3, labeled red) and a control RP11–
121O8 (16p13.1, labeled green) probe showing a triplication (white arrow) in the patient 20. (H) Representative FISH image using the same probes shows a normal hy-
bridization pattern observed in both parents.
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Amissense mutation in the HMG-box domain of SOX8 is
associated with a lack of testis-determination
Based on the above observations, we extended the SOX8 muta-
tion screen to a large cohort of 46, XY DSD individuals (Table 2).
Three heterozygous missense SOX8 variants were identified in a
screen of 204 cases of unexplained 46, XY DSD. Two of these
changes were observed in the control cohort and their
contribution to the phenotype is considered unlikely. The third
mutation, a heterozygous c.468G>C p.Glu156Asp amino acid
substitution was identified in a 46, XY phenotypic female who
presented at 16 years of age with primary amenorrhea (Patient 3
Table 1, Fig. 4A). The Glu156 residue is located in the HMG-box
and is evolutionarily conserved not only within the SOX8 pro-
tein but also in other members of groups E and F SOX protein
family (Fig. 4B). The mode of inheritance of this mutation is un-
known as the parents were unavailable for study. This mutation
was not observed in our control cohort, but it is present as a
Figure 2. Gonad histology of Patients 1 and 2. Patient 1, (A) Ovarian-like stromal cells with no evidence of testicular tissue consistent with 46, XY complete gonadal dys-
genesis. Patient 2, (B) Seminiferous tubules (cords) are mildly contorted in places (black arrow) and some are misshapen. The interstitium space is expanded and mildly
fibrotic (white arrow; H&E; 200X). (C) Immunohistochemistry for calretinin shows only focal Leydig cells (arrows; calretinin stain, blue; 200X). (D) Inhibin immunohisto-
chemistry highlights Sertoli cells, making the contorted tubules more evident (inhibin; 200X). (E) Immunohistochemistry for SOX9 staining the nuclei of Sertoli cells
within tortuous tubules (SOX9; 200X).
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rare variant in the ExAC database (2: 121, 228 alleles,
rs764098477). The SOX8 p.Glu156Asp mutation is not expected
to disrupt DNA binding per se because this residue does not map
to the DNA interaction interface (Fig. 4C). Furthermore, ex-
changing the equivalent residues in Sox2 (Sox2Lys to Glu) and
Sox17 (Sox17Glu to Lys) are reported not to show any effect on
DNA binding by the SOX HMG box in the absence of partner pro-
teins (28). However, this mutation could affect how SOX8 dimer-
izes with its partner factors on DNA, since changing the same
residue in Sox2 and Sox17 affected the ability of these proteins
to interact with OCT4 [Fig. 4C (28)].
A series of in vitro analyses were performed to assess the ef-
fect of this mutant on the biological activity of the SOX8 protein.
Transient transfection assays were performed since a number
of SOXE group-responsive genomic elements have been identi-
fied that, when placed upstream of a reporter gene, can be used
to quantitate transcriptional regulatory function of protein vari-
ants (29). The function of SOX genes involves a complex interac-
tion with many other transcriptional co-regulators, including
other SOX proteins (29) and therefore we considered that the
consequence of the SOX8 mutation may be promoter or cell con-
text dependent. Our data show that the mutant SOX8 protein
exhibits a context-specific loss-of-function activity. The WT-
and mutant SOX8 proteins can activate a series of gonadal pro-
moters (Fig. 5A). However, the SOX8p.Glu156Asp specifically
fails to synergize with NR5A1 to transactivate the Sox9 Tesco
enhancer element (Fig. 5A), yet both WT-SOX8 and
SOX8p.Glu156Asp proteins physically interact with the NR5A1
Table 2. SOX8 mutations in 46, XY DSD, male infertility, primary ovarian insufficiency and in the control cohort of ancestry-matched fertile/
normospermic individuals
46, XY DSD
(n¼ 204)
Azoospermia
(n¼ 131)
Oligozoospermia
(n¼ 143)
POI
(n¼ 153)
POI replication
study (n¼ 104)
Fertile and/or
normospermic controls
(n¼ 813; European ancestry 503;
North African/Arab ancestry 310)
p.Glu156Asp p.Lys241Thr p.Gly359Arg (x2) p.Arg8_Ser9deldeletion of 2 AA p.Pro11Leu p.Ala240Thrd
p.Pro336Leu p.Asp382Asn p.Ala373Ser p.Ala32Val p.Pro196Leu p.Thr331Mete
p.Thr340Ser p.Gly378Ser p.Pro242Leu (x2, sisters) p.Pro242Leu p.Pro336Leuf
p.Asp382Asn p.Ser267Leu p.Ala416Thr p.Thr340Serf
p.Val282Ile p.Ala373Thrd
p.Asp382Asn (x3) p.Ala428Thrf
p.Ala416Thr
1.47% 1.53% 3.5%a 5.9%b 3.85%c 0.74%
aP¼0.0151, bP¼0.000107, cP¼ 0.0191 compared with controls (Fishers t-test, two-tailed), POI: Primary ovarian insufficiency; DSD: Disorder of Sex Development; AA:
Amino acids. All mutations are heterozygous. Fertile fathers from, d1000 genomes project (European ancestry), eDanish Genome Project and fin-house controls.
Figure 3. Expression of the SOX8 protein in human gonad tissues. (A) The SOX8 protein (red) is expressed in the human male Sertoli and Leydig cells together with
NR5A1 (green) during early testis formation (image at 9 weeks post-conception). Primitive seminiferous cords are indicated by the dashed lines (B) The SOX8 protein ex-
pression in the granulosa cells of the late fetal ovary (image at 40 weeks of gestation). (C) Immunohistochemistry showing SOX8 expression in granulosa cells (arrow)
lining the follicles of the adult ovary (19 years old; scale bars are 50 lm).
1233Human Molecular Genetics, 2018, Vol. 27, No. 7 |
protein (Fig. 6, Supplementary Material, Fig. S2). The mutation
also impacted on the functional interaction between SOX8 and
SOX9. Both SOXE proteins have the ability to heterodimerize
and combinatorially regulate their target gene expression
(30,31). We show that the WT-SOX8 protein binds to SOX9,
however the SOX8p.Glu156Asp protein cannot (Fig. 6,
Supplementary Material, Fig. S2). The SOX8p.Glu156Asp mutant
also exerts a repressive effect by negatively affecting the syner-
gistic activation of the Tesco enhancer by NR5A1 and SOX9
(Fig. 5B). Finally, the SOX8p.Glu156Asp protein also has a domi-
nant negative effect on the WT-SOX8 protein since it reduced,
in a dose-dependent manner, the synergistic activation of the
Tesco reporter by WT-SOX8 and NR5A1 (Supplementary
Material, Fig. S3). All these results are consistent with the hy-
pothesis that the mutant SOX8 protein has an altered biological
activity impairs testis-determination.
SOX8mutations associated with human infertility
To investigate whether mutations in SOX8, like NR5A1, could
also contribute to a wider spectrum of male and female
infertility, we sequenced the coding region of SOX8 in 427 men
and women with infertility. The incidence of mutations in the
control cohort of fertile and/or normospermic men was 0.74%.
In contrast, rare or novel SOX8 variants were observed in 1.47%
of azoospermic men, 3.5% of oligozoospermic men (P¼ 0.0151,
Fishers t-test, two-tailed) and 9/153 women with POI in an initial
cohort (5.9%; P¼ 0.000 107) and in 4/104 (3.85%; P¼ 0.0191) of
women with POI in a replication cohort (Tables 2 and 3).
Combining the data from both cohorts, we found a significant
association of mutations in SOX8 with POI (5.06%; P¼ 4.5105).
The majority of mutations associated with infertility flank
the HMG-box and fall within one of the two transactivation do-
mains. Although many of these missense mutations are pre-
dicted by computational methods to have a deleterious effect
on protein function, the interpretation of the significance of
mutations in human disease remains very challenging. We
therefore sought to test the consequence of the SOX8 mutations
associated with infertility in a series of functional assays. As ex-
pected, the transient transfection assays using the AMH, Dmrt1
and NR5A1 promoters as reporters in HEK 293-T and mES cells
indicated biological differences between mutated wild-type
proteins that, in some cases, were promoter specific, e.g. the
Figure 4. Mutation in the HMG-box of SOX8 associated with 46, XY gonadal dysgenesis. (A) Schematic representation showing important functional domains of the
SOX8 protein. The amino acid sequence of the HMG domain including the three alpha-helices, the two nuclear localization signals (NLS1, NLS2), and the nuclear export
sequence (NES) together with the position of SOX8p.Glu156Asp (p.E156D) mutation are indicated. The DNA-dependent dimerization domain (DIM), the DNA-binding
HMG domain, and the transactivation domains (TA1, TA2) are shown. (B) Left, alignment of the C-terminal of the SOX8 HMG-box domain containing helix 3 from se-
lected vertebrates. Right, the alignment of the distal portion of the SOX8 HMG-box domain with other human SOXE and SOXF family members. The position of the
p.Glu156Asp missense mutation is highlighted. (C) Structural models for ternary complexes of conjectured SOX8p.Glu156Asp -SOX8, SOX8p.Glu156Asp -SOX9 and
SOX8p.Glu156Asp -OCT4 dimers on composite DNA elements. SOX8 is shown in dark red, SOX9 in orange and OCT4 in blue. The HMG domains of SOX E proteins and
the POU domain of OCT4 are shown as cartoon with cylindrical alpha-helices and the DNA as gray van-der-Waals surface. The SOX8p.Glu156Asp site is drawn as ball-
and-sticks. The DNA sequences used to generate the models with colour-coded binding elements are depicted underneath the models. The SOXE HMG box is N-termi-
nally extended by a 40 amino acid dimerization (DIM) domain of unknown structure that mediates highly cooperative DNA-dependent dimerization presumably by
interactions with the HMG box.
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p.Asp382Asn mutation shows a specific loss-of-function
with the AMH promoter (Supplementary Material, Fig. S4).
Furthermore, some mutant proteins show changes in cellular
localization (Supplementary Material, Fig. S5).
Although, a contribution of Sox8 to male infertility in the
mouse has been established for some time, the finding of an asso-
ciation between human POI and SOX8 variants is a novel finding
since Sox8/ female mice are fertile (7). We therefore sought to
examine the profile of SOX8 expression in the human ovary to
see if this is consistent with a role for mutations in the protein
contributing to female infertility. We observed that the SOX8 pro-
tein is expressed in the 40-week foetal ovary and in the adult
ovary (Fig. 3B and Supplementary Material, Fig. S1). The SOX8 pro-
tein is highly expressed in granulosa cells at both stages.
Discussion
Our data provide the first evidence that SOX8 plays a role in hu-
man sex determination and in the function of the adult gonad.
Mouse models also suggest that Sox8 plays a key role in early
Figure 5. SOX8p.Glu156Asp shows altered biological activity. (A) The transcriptional activities of WT-SOX8 and SOX8p.Glu156Asp were studied using the human AMH
and NR5A1 promoters, mouse Dmrt1 promoter and the Sox9 Tesco enhancer as reporters, following transfection in HEK293-T cells. The data shown represent the
mean6SEM of minimum three independent experiments, each of which was performed at least in quadruplicate. The reporter constructs were transfected into
HEK293-T cells with either the WT-SOX8 or SOX8p.Glu156Asp expression vector. The results are expressed as relative percentage of WT-SOX8 activity (100%). The
SOX8p.Glu156Asp can activate the gonadal promoters in a similar fashion to WT-SOX8. However, although SOX8p.Glu156Asp can synergistically activate the AMH pro-
moter with NR5A1, it fails to synergise with NR5A1 to activate the Sox9 Tesco enhancer. (B) HEK 293-T cells were co-transfected with Tesco reporter construct (10ng),
WT-NR5A1 (1ng) and WT-SOX9 (1ng) and increasing amount of WT-SOX8 or SOX8p.Glu156Asp (0, 1, 2, 5, 10 ng). Results are expressed as Relative Luminescence Units
(RLU). The SOX8p.Glu156Asp mutant exerts a repressive effect by preventing synergistic activation of the Sox9 Tesco enhancer by NR5A1 and SOX9 even at three times
lower concentrations.
1235Human Molecular Genetics, 2018, Vol. 27, No. 7 |
Figure 6. Protein–protein interaction assayed using Proximity ligation assay. Plasmids encoding SOX8-WT or SOX8p.Glu156Asp were transiently expressed with
WT-NR5A1 or SOX9 for 48 h in HEK293T cells. Protein–protein interaction of SOX8-WT and SOX8p.Glu156Asp with NR5A1 and SOX9 were analysed using the Duolink
proximity ligation assay. Nuclei are stained with DAPI (blue) and Duolink signal representing interaction between the proteins is shown in green. Each green dot repre-
sents a single dimerization event. Both the SOX8-WT and SOX8p.Glu156Asp proteins can physically interact with NR5A1. Whereas, although SOX8-WT protein can in-
teract with SOX9, the SOX8p.Glu156Asp cannot.
Table 3. Mutations in the SOX8 gene associated with human male or female infertility. Heterozygous missense mutations were identified in
the AIRE and NR5A1 genes in cases 18 and 20, respectively. In such cases the SOX8 mutation may contribute to the severity of the phenotype
Patient Mutation Variant
identifier
Global minor
allelic frequency
PolyPhen2
Score
Ancestry Phenotype and comments
4 p.Lys241Thr rs553836905 0.0002 0.762 European Azoospermia
5 p.Gly359Arg rs199719055 0.000014 0.961 Eastern European Oligozoospermia 3.4 106/ml
6 p.Gly359Arg rs199719055 0.000014 0.961 French Oligozoospermia 2106/ml
7 p.Ala373Ser rs200828189 0.0036 0.000 French Oligozoospermia 9106/ml
8 p.Gly378Ser rs576173763 0.0064 0.004 Senegalese Severe oligozoospermia 0.005 106/ml
9 p.Asp382Asn rs143203270 0.0057 0.986 Tunisian Oligozoospermia. 6 106/ml
10 p.Asp382Asn rs143203270 0.0057 0.986 Algerian Azoospermia
11 p.Arg8_Ser9dela — — — Italian POI. Menarche at 13 years; one pregnancy; secondary
amenorrhea and POI at 37 years. Mother had men-
opause at 35 years
12 p.Pro11Leu rs200231150 0.010 0.636 European POI. Primary amenorrhea
13 p.Ala32Val* — 0.000009 0.919 Italian POI. Menarche at 14 years; secondary amenorrhea
and POI at 21 years
14 p.Pro196Leu — 0.0000275 0.001 European POI. Primary amenorrhea. Atrophic ovaries
15 p.Pro242Leu rs567451602 0.0057 0.001 Paraguay POI. Primary amenorrhea
16 p.Pro242Leu rs567451602 0.0057 0.001 Paraguay POI. Primary amenorrhea (sister of case 12)
17 p.Pro242Leu rs567451602 0.0057 0.001 European POI. Primary amenorrhea. Atrophic ovaries
18 p.Ser267Leu rs368972027 0.000017 0.942 Italian POI. Amenorrhea at 30. Hypoparathyroidism during
childhood
19 p.Val282Ilea — — 0.990 Argentinian POI. Secondary amenorrhea
20 p.Asp382Asn rs143203270 0.0057 0.986 North African POI. Menarche at 12 years; secondary amenorrhea at
14 years.
21 p.Asp382Asn rs143203270 0.0057 0.986 European POI. Primary amenorrhea at 16 year. Absent pubertal
development, ovaries not seen by ultrasound
22 p.Asp382Asn rs143203270 0.0057 0.986 French POI. Menarche at 11 years; secondary amenorrhea at
14 years
23 p.Ala416Thr rs201602067 0.0004 0.005 Italian POI. Menarche at 9 years; secondary amenorrhea
and POI at 38 years
24 p.Ala416Thr rs201602067 0.0004 0.005 European POI. Primary amenorrhea
aNovel variant.
POI, primary ovarian insufficiency. All mutations are heterozygous.
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testis-determination as well as maintaining male fertility.
We identified three patients with 46, XY DSD who carried rear-
rangements/mutations involving the SOX8 gene.
One patient had a paracentric inversion with a breakpoint
150 Kb upstream of the SOX8 gene. The only other gene within
the region is LMF1. Since, homozygous, loss-of-function muta-
tions in the LMF1 gene are associated with hypertriglyceridemia
and decreased lipase activity, this gene was not considered to
be responsible for the phenotype (25).
A second patient carried four copies of an 854 Kb region im-
mediately 50 to the SOX8 gene including SOX8 enhancer ele-
ments as well as the a-globin gene cluster (26). Duplication of
a-globin genes is a rare cause of anaemia that may lead to im-
balances of a- and b-chains in haemoglobin tetramer, especially
in b-thalassemia carriers (32,33). Alternatively, the 16p13.3 chro-
mosomal rearrangement may result in disruption of the long-
range regulation leading to a partial silencing of gene expres-
sion consistent with prenatal and postnatal anaemia observed
in patient 2 (34). The other somatic anomalies seen in this pa-
tient may be a result of gene dosage of one or more of the other
genes located in the duplicated region (Supplementary Material,
Table S1). Indeed, a patient with 46, XY gonadal dysgenesis,
skeletal and cardiac anomalies and developmental delay was
reported to carry a similar 560 kb duplication located approxi-
mately 18 kb upstream of SOX8 (35). These rearrangements at
the SOX8 locus may cause dysregulation of SOX8 expression.
This hypothesis is consistent with the multiple reports of 46, XY
gonadal dysgenesis associated with chromosomal rearrange-
ments even up to several Mb upstream of genes involved in sex
determination including SOX9 and NR0B1 (36–39). Furthermore,
the centromeric breakpoint in patient 2 falls between the con-
served E1 and E2 SOX8 enhancer elements, which are required
for murine Sox8 gene expression (26). Dysregulation of SOX8 ex-
pression could negatively impact on male gonadal development
and lead to various degrees of 46, XY DSD. Indeed, 46, XY
individuals carrying deletions that include SOX8 (ATR16 syn-
drome) occasionally present with mild anomalies such as hypo-
spadias or cryptorchidism and Patients 1 and 2 may represent
part of this broad DSD spectrum (40).
The third patient presenting with 46, XY gonadal dysgenesis
had a missense mutation involving a highly conserved glutamic
acid residue within helix 3 of the SOX8 HMG-box. The severe go-
nadal phenotype in this patient, which is due to lack of
appropriate testis-determination, may be due to the specific
dominant negative activity of the SOX8p.Glu156Asp protein on
the WT-SOX8 protein and/or the repressive effect of this mutant
protein on SOX9/NR5A1 synergy at the Sox9 Tesco enhancer that
we observed using in vitro assays (Fig. 7). These data, which pro-
vide evidence for a role of SOX8 in early human testis develop-
ment are supported by murine studies. The absence of both
Sox9 (pro-testis) and Rspo1 (pro-ovary) in XX foetuses results in
the development of ovotestes and hypoplastic testis (4). SoxE
group genes, Sox10 and Sox8 that are normally repressed by
Rspo1, are activated in the double knockout gonads, suggesting
that Sox8 may serve as a driver of testis formation in the ab-
sence of Sox9 (4). Recent data suggest that Sox8 may also be in-
volved in repressing the ovarian pathway, via the repression of
Foxl2 expression during early testis formation (41).
In this study, we have also identified mutations in SOX8 as-
sociated with cases of male and female infertility. Although the
mechanism(s) leading to infertility in either sex is unclear, all
mutations associated with infertility showed differences in bio-
logical activity compared with the WT protein and all mutations
flank the HMG-box. Transient transfection assays using as a tar-
get the promoters of genes important for gonad function
showed a wide range of effects including promoter specific loss-
of-function or alterations in the cellular localization of the
mutated protein. Inferring precisely how these mutations cause
infertility is difficult since the gene regulatory pathways down-
stream of SOX8 have not been defined in either the XY or XX
Figure 7. Schematic representation of the results of the in vitro assays for the SOX8p.Glu156Asp protein. (A) The mutant SOX8 protein has the ability to physically inter-
act with the NR5A1 protein but in contrast to the WT-SOX8 protein does not synergize with NR5A1 to promote reporter gene activity using the Tesco enhancer as a tar-
get. (B) The mutant SOX8 protein does not physically interact with the SOX9 protein and shows a lack of synergy with SOX9/NR5A1 to promote reporter gene activity.
(C) The SOX8 mutant protein also shows dominant negative activity by impairing promoter gene activity of the WT-SOX8 protein in synergy with NR5A1.
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gonad. In mice Sox8 is essential for the maintenance of male fer-
tility beyond the first wave of spermatogenesis (10). At 5 months
of age Sox8/ mice show a progressive degeneration of the
seminiferous epithelium through perturbed physical interac-
tions between Sertoli cells and the developing germ cells (10).
Here, we identified rare or novel SOX8 mutations in 3.5%
(P< 0.05) of men with unexplained reduced sperm counts as
compared with a frequency of 0.78% in ancestry-matched nor-
mospermic/fertile control cohorts. It is important to compare
our data with a cohort of individuals who are known to be fertile
and/or normospermic since infertility is a common phenotype
and public databases, such as ExAC, are likely to contain a back-
ground pool of rare variants that can cause infertility and/or
DSD. These cases of male infertility may represent mild forms
of testicular dysgenesis or, similar to the mouse model the
SOX8 protein may also be a regulator of Sertoli–germ cell
adhesion independently of its role in primary testis-
determination (10).
Our analyses also revealed mutations in SOX8 in 5.06% of all
women with POI from two replication studies (P¼ 4.5105).
This suggests that mutations in human SOX8 may have a
greater impact on ovarian rather than testis function. Although
Sox8/ female mice are fertile, Sox8 expression has been re-
ported in preantral follicles, preovulatory follicles, cumulus
granulosa cells and at high levels in mural granulosa cells,
which line the wall of the follicle and are critical for steroido-
genesis and ovulation (7,42). We have shown that SOX8 protein
is expressed specifically in the granulosa cell of the developing
and adult ovary in the human. The observation that Sox8 ex-
pression is higher in the mural cells that line the follicle wall
than in the cumulus cells that surround the oocyte suggests
that SOX8 may play a role in granulosa cell differentiation (42).
We can hypothesize that in female, in the absence of SOX9,
SOX8 may be an important regulator of AMH expression (re-
quired for maintenance of the germ cell pool) in the adult ovary
and, therefore, mutations in SOX8 may result in POI.
The results presented in this study provide novel insight
into the genetic mechanisms of human gonadal development
and function and provide further evidence that a spectrum of
reproductive phenotypes from DSD to infertility can be associ-
ated with variations in a single genetic factor.
Materials and Methods
Detailed study methods are provided in SI methods
Subjects and samples
All patients with 46, XY DSD met the revised criteria of the
Pediatric Endocrine Society (LWPES)/European Society for
Paediatric Endocrinology (ESPE). This study was approved by the
local French ethical committee (2014/18NICB – registration num-
ber IRB00003835) and consent to genetic testing was obtained
from adult probands or from the parents when the patient was
under 18 years. Patient ancestry was determined by self-report-
ing, based on responses to a personal questionnaire, which asked
questions pertaining to the birthplace, languages and self-
reported ethnicity of the participants, their parents and grand-
parents. Genes known to be involved in 46, XY DSD were
screened for mutations in the XY DSD cohort and high-resolution
aCGH was performed on all cases and indicated normal ploidy in
all cases. An extended description of patient 2 is provided in SI
methods. The infertile male population consisted of 274 men of
European or North African ancestry. For each man, ejaculates
were obtained by masturbation after 2–7 days of sexual
abstinence. All underwent an andrological work-up, which in-
cluded medical history, physical examination, hormonal evalua-
tion (FSH, LH, and testosterone) and semen analysis. Men with
known clinical (cryptorchidism, infections, varicocele) or genetic
(karyotype anomalies, Y chromosome microdeletions) causes of
infertility were excluded. Oligozoospermia was defined as having
less than 15106 sperm/ml. Primary amenorrhea was diagnosed
when pubertal development was absent despite the patient being
of pubertal age (greater than 13 years) with increased basal
plasma FSH concentration (>9 IU/l). Cases of secondary amenor-
rhea (no menstruation after six cycles) and premature ovarian
failure (amenorrhea, hypoestrogenism, and elevated serum go-
nadotropin levels in women younger than 40 years of age) were
included.
The control panel consisted of 280 unrelated normospermic
46, XY males of French ethnic origin with known fertility and no
history of testicular anomalies (determined by self-reporting)
from the Biobank for Research on Human Reproduction
(GERMETHEQUE). An additional in-house 180 normospermic
men and 130 fertile men of Arab/North African ancestry were
included as controls. European ancestry-matched in-house con-
trols of known fertility status were also included (n¼ 20). Other
control populations included fathers of European ancestry from
the 1000 genomes project (Iberian and Northern Europeans
from Utah, n¼ 103), the Danish Genome Project (n¼ 50) and
from the University of Dundee (n¼ 50).
Genomic analysis
Chromosome analysis, ArrayCGH, genomic, exome and Sanger
sequencing are all described in SI Materials and Methods.
Immunohistochemistry
Human fetal testis tissue (9 weeks post-conception) was pro-
vided with approval from the Human Developmental Biology
Resource (HDBR, www.hdbr.org). Term fetal (40 weeks) ovary
was obtained from Abcam (#ab4412) and adult ovary tissue
(19 years) was obtained from Tissue Solutions. Tissue sections
(12 mm) were fixed briefly in 4% PFA in TBS, rinsed in TBS and
blocked in 1% BSA in TBS-Tween (0.5% Tween) for 1 h before in-
cubating overnight with rabbit monoclonal SOX8 antibody
(Sigma HPA41640; 1: 200 dilution) and, where relevant, mouse
monoclonal NR5A1 (SF1) antibody (Thermo Fisher #434200; 1:
200 dilution). Sections were washed in TBS-Tween and incu-
bated for 1 h with the relevant secondary antibodies: Alexa555
goat anti-rabbit (Invitrogen, A21429; 1: 400) and Alexa488 goat
anti-mouse (Invitrogen, A11001; 1: 400). Nuclei were counter-
stained with DAPI (Sigma). Slides were washed and mounted
using ProLong Gold Antifade Mountant (Lifetech, #P36930).
Images were collected on a Zeiss LSM 710 confocal microscope
(Carl Zeiss) and analysed using Zeiss Zen 2009 and Image J.
Details of the plasmids, cell lines, cellular localization as-
says, structural modelling and co-immunopreciptation are pro-
vided in the SI methods.
Statistics
The results of the luciferase assays were compared for their sta-
tistical significance by calculating two-tailed Student’s t-test us-
ing GraphPad Prism software. 95% confidence interval was
calculated using the mean difference between the two groups
being tested. The data for each of the groups tested and their t
values, along with degrees of freedom (df), standard error of dif-
ference, P-values and predicted statistical significance are sum-
marized in Supplementary Material, Table S2. Based on the P-
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values the GraphPad Prism software calculates the difference as
not significant, not likely to be significant, significant, very sig-
nificant and extremely significant.
Supplementary Material
Supplementary Material is available at HMG online.
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